RxDoctor Payments Data

Pravir Baxi, MD

Nephrology · Chicago, ILNPI 1780970731

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (48.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Lilly USA, LLC at 31.2% of the total. Reporting peaked in 2024 at $18,450 and has fallen 62.6% since, to $6,891 in 2025. Among nephrology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$31,946in general payments, 2019–2025

Across 79 payments — averaging $404.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$10K
  • Calliditas Therapeutics US Inc.$9K
  • Boehringer Ingelheim$5K
  • Travere Therapeutics, Inc.$4K
  • Aurinia Pharma U.S., Inc.$3K
  • Amgen$178
  • plus $713 from 11 others

What the payments were for

  • Consulting fees$10,20932%
  • Speaking & faculty fees$15,58549%
  • Travel & lodging$2,9889%
  • Food & beverage$3,16510%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,946 in reported general payments places this provider in the 90th percentile of 524 nephrology providers in Illinois.

See all nephrology providers in Illinois

Medicare billing

Part B allowed, 2024
$194,109
Medicare patients
398
Services billed
1,971

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LokelmaSodium Zirconium Cyclosilicate42$22,002
VeltassaPatiromer Calcium Sorbitex18$13,845
ProsolParenteral Amino Acid 20% No.128$3,680
Losartan Potassium42$507
Valsartan16$281
Furosemide38$279
Amlodipine Besylate26$248
Carvedilol15$29

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$108$22,00242 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 524 nephrology providers in Illinois.

Other nephrology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →